Research Roundups

GLP1 Research Roundup (February 2024)

GLP1.Guide Staff

Apr 22, 2024 — 3 min read

GLP1 Receptor Agonist drugs (Semaglutide, Ozempic, Mounjaro, Wegovy, etc) have seen extensive testing and research in the past, due to their usage by people with type 2 Diabetes.

🍃

Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?

Check out our quick explainer

Finding all this research is hard, so here at GLP1.Guide we're trying to put together a list. Here's what we've found – most recent research first.

Summary

Semaglutide and beyond: a turning point in obesity pharmacotherapy

Tirzepatide, a dual incretin analog, is a boon in metabolic syndrome: an editorial

The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects

Tirzepatide: A Review in Type 2 Diabetes

Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives

GLP-1 Agonists for Obesity—A New Recipe for Success?

Review/Meta-Analyses

Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

A COMPARISON OF GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2: A SYSTEMATIC REVIEW

Trials

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

Case Studies

Observational Studies

🐀 GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study

Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report

Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study

Benefits

💡

The study above did not find any conclusive evidence for GLP1 RAs being specifically beneficial in the case of hypothalmic obesity

Lowering HbA1c

Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide

Kidney Disease

Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression

The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function

Parkinsons

GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression

Binge Eating/Bulimia

GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review

Effects

Harms

Hypogonadism

Use of GLP-1 Agonists Associated with Diagnosis of Hypogonadism in Large Retrospective Cohort

Suicidal Ideation

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

👍

Researchers could find no heightened association between GLP1 Receptor Agonist use and Self Injurious Behaviors. This paper failed to find an identifiable correlation between GLP1 and self harm.